Skip to main content
Top
Published in: Archives of Virology 7/2010

01-07-2010 | Brief Review

Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis

Authors: Janet Patricia Hapgood, Michele Tomasicchio

Published in: Archives of Virology | Issue 7/2010

Login to get access

Abstract

The glucocorticoid receptor (GR) is a steroid receptor that regulates diverse functions, which include the immune response. In humans, the GR acts via binding to cortisol, resulting in the transcriptional modulation of key host genes. Several lines of evidence suggest that the host GR could be a key protein exploited by HIV at multiple levels to ensure its pathogenic success. Endogenous and therapeutic glucocorticoids play important roles in patients with HIV due to their well-established effects on immune function. AIDS patients develop glucocorticoid hypersensitivity, consistent with a mechanism involving an HIV-1-induced increase in expression or activity of the GR. Both the HIV-1 accessory protein Vpr and the host GR affect transcription of viral proteins from the long terminal repeat (LTR) region of the HIV-1 promoter. In addition, Vpr modulates host GR function to affect transcription of host genes, most likely via direct interaction with the GR. Vpr appears to regulate GR function by acting as a co-activator for the GR. Since both the GR and Vpr are involved in apoptosis in T cells and dendritic cells, crosstalk between these proteins may also regulate apoptosis in these and other cells. Given that cortisol is not the only ligand that activates the GR, other endogenous as well as synthetic GR ligands such as progestins may also modulate HIV pathogenesis, in particular in the cervicovaginal environment. Investigating the molecular determinants, ligand-selectivity and role in HIV pathogenesis of the GR–Vpr interaction may lead to new strategies for development of anti-HIV drugs.
Literature
1.
go back to reference De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307–320PubMedCrossRef De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307–320PubMedCrossRef
2.
go back to reference Marsden MD, Zack JA (2009) Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63:7–10PubMedCrossRef Marsden MD, Zack JA (2009) Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63:7–10PubMedCrossRef
4.
go back to reference Montessori V, Press N, Harris M, Akagi L, Montaner JS (2004) Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170:229–238PubMed Montessori V, Press N, Harris M, Akagi L, Montaner JS (2004) Adverse effects of antiretroviral therapy for HIV infection. CMAJ 170:229–238PubMed
5.
go back to reference Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728PubMedCrossRef Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728PubMedCrossRef
6.
go back to reference Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354–2360PubMedCrossRef Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354–2360PubMedCrossRef
7.
go back to reference Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37:1112–1118PubMedCrossRef Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37:1112–1118PubMedCrossRef
8.
go back to reference Spearman P (2006) Current progress in the development of HIV vaccines. Curr Pharm Des 12:1147–1167PubMedCrossRef Spearman P (2006) Current progress in the development of HIV vaccines. Curr Pharm Des 12:1147–1167PubMedCrossRef
9.
go back to reference Kaleebu P, Abimiku A, El-Halabi S, Koulla-Shiro S, Mamotte N, Mboup S, Mugerwa R, Nkengasong J, Toure-Kane C, Tucker T, Wassenaar D, Williamson C, Wolday D (2008) African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med 5:e236PubMedCrossRef Kaleebu P, Abimiku A, El-Halabi S, Koulla-Shiro S, Mamotte N, Mboup S, Mugerwa R, Nkengasong J, Toure-Kane C, Tucker T, Wassenaar D, Williamson C, Wolday D (2008) African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med 5:e236PubMedCrossRef
10.
go back to reference Lu S (2008) Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev Vaccines 7:151–153PubMedCrossRef Lu S (2008) Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev Vaccines 7:151–153PubMedCrossRef
11.
go back to reference Sekaly R (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205:7–12PubMedCrossRef Sekaly R (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205:7–12PubMedCrossRef
12.
go back to reference Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893PubMedCrossRef Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893PubMedCrossRef
13.
go back to reference Harari A, Bart P, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl J, Esteban M, Heeney J, Frachette M, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205:63–77PubMedCrossRef Harari A, Bart P, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl J, Esteban M, Heeney J, Frachette M, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205:63–77PubMedCrossRef
14.
go back to reference Harari A, Vallelian F, Meylan PR, Pantaleo G (2005) Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174:1037–1045PubMed Harari A, Vallelian F, Meylan PR, Pantaleo G (2005) Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174:1037–1045PubMed
15.
go back to reference Ravanfar P, Mendoza N, Satyaprakash A, Jordan BI (2009) HIV vaccines under study. Dermatol Ther 22:158–167PubMedCrossRef Ravanfar P, Mendoza N, Satyaprakash A, Jordan BI (2009) HIV vaccines under study. Dermatol Ther 22:158–167PubMedCrossRef
17.
go back to reference Clark JK, Schrader WTOB (1992) Mechanism of steroid hormones. In: Wilson JD (ed) Textbook of Endocrinology. WB Sanders Co., Philadelphia, pp 35–90 Clark JK, Schrader WTOB (1992) Mechanism of steroid hormones. In: Wilson JD (ed) Textbook of Endocrinology. WB Sanders Co., Philadelphia, pp 35–90
18.
go back to reference Munck A, Guyre PM, Holbrook NJ (1984) Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5:25–44PubMedCrossRef Munck A, Guyre PM, Holbrook NJ (1984) Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5:25–44PubMedCrossRef
19.
go back to reference Kim YS, Kim J, Kim Y, Lee YH, Kim J, Lee S, Shin SY, Ko J (2008) The role of calpains in ligand-induced degradation of the glucocorticoid receptor. Biochem Biophys Res Commun 374:373–377PubMedCrossRef Kim YS, Kim J, Kim Y, Lee YH, Kim J, Lee S, Shin SY, Ko J (2008) The role of calpains in ligand-induced degradation of the glucocorticoid receptor. Biochem Biophys Res Commun 374:373–377PubMedCrossRef
20.
go back to reference Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, Kim N, Rao S, Player A, Zheng Y, Garabedian MJ, Kawasaki E, Pant HC, Chrousos GP (2007) Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 21:1552–1568PubMedCrossRef Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, Kim N, Rao S, Player A, Zheng Y, Garabedian MJ, Kawasaki E, Pant HC, Chrousos GP (2007) Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 21:1552–1568PubMedCrossRef
21.
go back to reference McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20:435–459PubMedCrossRef McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20:435–459PubMedCrossRef
22.
go back to reference De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24:488–522PubMedCrossRef De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24:488–522PubMedCrossRef
23.
go back to reference Smoak KA, Cidlowski JA (2004) Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125:697–706PubMedCrossRef Smoak KA, Cidlowski JA (2004) Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125:697–706PubMedCrossRef
24.
go back to reference Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119:1198–1208PubMed Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119:1198–1208PubMed
25.
go back to reference Pantaleo G, Graziosi C, Fauci AS (1993) New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328:327–335PubMedCrossRef Pantaleo G, Graziosi C, Fauci AS (1993) New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328:327–335PubMedCrossRef
26.
go back to reference Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351–1362PubMedCrossRef Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351–1362PubMedCrossRef
27.
go back to reference Sellmeyer DE, Grunfeld C (1996) Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 17:518–532PubMed Sellmeyer DE, Grunfeld C (1996) Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 17:518–532PubMed
28.
go back to reference Zhou J, Cidlowski JA (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70:407–417PubMedCrossRef Zhou J, Cidlowski JA (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70:407–417PubMedCrossRef
29.
go back to reference Kumar R, Thompson EB (2005) Gene regulation by the glucocorticoid receptor: structure: function relationship. J Steroid Biochem Mol Biol 94:383–394PubMedCrossRef Kumar R, Thompson EB (2005) Gene regulation by the glucocorticoid receptor: structure: function relationship. J Steroid Biochem Mol Biol 94:383–394PubMedCrossRef
30.
go back to reference Revollo JR, Cidlowski JA (2009) Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 1179:167–178PubMedCrossRef Revollo JR, Cidlowski JA (2009) Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 1179:167–178PubMedCrossRef
31.
go back to reference Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525–533PubMedCrossRef Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525–533PubMedCrossRef
32.
go back to reference Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E (2010) The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75:1–12PubMedCrossRef Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E (2010) The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75:1–12PubMedCrossRef
33.
go back to reference Bamberger CM, Bamberger AM, de Castro M, Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95:2435–2441PubMedCrossRef Bamberger CM, Bamberger AM, de Castro M, Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95:2435–2441PubMedCrossRef
34.
go back to reference Chrousos GP, Kino T (2005) Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005:pe48PubMedCrossRef Chrousos GP, Kino T (2005) Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE 2005:pe48PubMedCrossRef
36.
go back to reference Lonard DM, Lanz RB, O’Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28:575–587PubMedCrossRef Lonard DM, Lanz RB, O’Malley BW (2007) Nuclear receptor coregulators and human disease. Endocr Rev 28:575–587PubMedCrossRef
37.
go back to reference Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736PubMedCrossRef Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736PubMedCrossRef
38.
go back to reference Hayashi R, Wada H, Ito K, Adcock IM (2004) Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500:51–62PubMedCrossRef Hayashi R, Wada H, Ito K, Adcock IM (2004) Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500:51–62PubMedCrossRef
39.
go back to reference Rogatsky I, Zarember KA, Yamamoto KR (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20:6071–6083PubMedCrossRef Rogatsky I, Zarember KA, Yamamoto KR (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20:6071–6083PubMedCrossRef
40.
go back to reference Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR (2002) Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci USA 99:16701–16706PubMedCrossRef Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR (2002) Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci USA 99:16701–16706PubMedCrossRef
41.
go back to reference He Y, Simons SS Jr (2007) STAMP, a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol Cell Biol 27:1467–1485PubMedCrossRef He Y, Simons SS Jr (2007) STAMP, a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol Cell Biol 27:1467–1485PubMedCrossRef
42.
go back to reference Sun Y, Tao Y, Kagan BL, He Y, Stoney Simons S Jr (2008) Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Mol Cell Endocrinol 295:59–69PubMedCrossRef Sun Y, Tao Y, Kagan BL, He Y, Stoney Simons S Jr (2008) Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Mol Cell Endocrinol 295:59–69PubMedCrossRef
43.
go back to reference Galliher-beckley AJ, Williams JG, Collins JB, Cidlowski JA (2008) Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 28:7309–7322PubMedCrossRef Galliher-beckley AJ, Williams JG, Collins JB, Cidlowski JA (2008) Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 28:7309–7322PubMedCrossRef
45.
go back to reference Kino T, Martino MU, Charmandari E, Mirani M, Chrousos GP (2003) Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol 85:457–467PubMedCrossRef Kino T, Martino MU, Charmandari E, Mirani M, Chrousos GP (2003) Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol 85:457–467PubMedCrossRef
46.
go back to reference Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T (2002) Hiv-1 Protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity. J Immunol 169:6361–6368PubMed Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T (2002) Hiv-1 Protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity. J Immunol 169:6361–6368PubMed
47.
go back to reference Ma X, Montaner LJ (2000) Proinflammatory response and IL-12 expression in HIV-1 infection. J Leukoc Biol 68:383–390PubMed Ma X, Montaner LJ (2000) Proinflammatory response and IL-12 expression in HIV-1 infection. J Leukoc Biol 68:383–390PubMed
48.
go back to reference Wiegers K, Schwarck D, Reimer R, Bohn W (2008) Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 375:73–84PubMedCrossRef Wiegers K, Schwarck D, Reimer R, Bohn W (2008) Activation of the glucocorticoid receptor releases unstimulated PBMCs from an early block in HIV-1 replication. Virology 375:73–84PubMedCrossRef
49.
go back to reference Kolesnitchenko V, Snart RS (1992) Regulatory elements in the human immunodeficiency virus type 1 long terminal repeat LTR (HIV-1) responsive to steroid hormone stimulation. AIDS Res Hum Retroviruses 8:1977–1980PubMedCrossRef Kolesnitchenko V, Snart RS (1992) Regulatory elements in the human immunodeficiency virus type 1 long terminal repeat LTR (HIV-1) responsive to steroid hormone stimulation. AIDS Res Hum Retroviruses 8:1977–1980PubMedCrossRef
50.
go back to reference Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP (1999) The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189:51–62PubMedCrossRef Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP (1999) The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189:51–62PubMedCrossRef
51.
go back to reference Sherman MP, DeNoronha C, Pearce D, Greene WC (2000) Human immunode ciency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol 74:8159–8165PubMedCrossRef Sherman MP, DeNoronha C, Pearce D, Greene WC (2000) Human immunode ciency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol 74:8159–8165PubMedCrossRef
52.
go back to reference Vanitharani R, Mahalingam S, Ayyavoo V (2001) HIV-1 Vpr transactivates LTR-directed expression through sequences present within −278 to −176 and increases virus replication. Virology 289:334–342PubMedCrossRef Vanitharani R, Mahalingam S, Ayyavoo V (2001) HIV-1 Vpr transactivates LTR-directed expression through sequences present within −278 to −176 and increases virus replication. Virology 289:334–342PubMedCrossRef
53.
go back to reference Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN (2002) Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76:9724–9734PubMedCrossRef Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN (2002) Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76:9724–9734PubMedCrossRef
54.
go back to reference Mitra D, Sikder SK, Laurence J (1995) Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression. Virology 214:512–521PubMedCrossRef Mitra D, Sikder SK, Laurence J (1995) Role of glucocorticoid receptor binding sites in the human immunodeficiency virus type 1 long terminal repeat in steroid-mediated suppression of HIV gene expression. Virology 214:512–521PubMedCrossRef
55.
go back to reference Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA (1991) Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 65:4350–4358PubMed Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA (1991) Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 65:4350–4358PubMed
56.
go back to reference Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E (1997) Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 71:6113–6127PubMed Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E (1997) Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 71:6113–6127PubMed
57.
go back to reference Berkhout B, Silverman RH, Jeang KT (1989) Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273–282PubMedCrossRef Berkhout B, Silverman RH, Jeang KT (1989) Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273–282PubMedCrossRef
58.
go back to reference Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA (1986) The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941–947PubMedCrossRef Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA (1986) The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941–947PubMedCrossRef
59.
go back to reference Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC (1986) The trans-activator gene of HTLV-III is essential for virus replication. Nature 320:367–371PubMedCrossRef Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC (1986) The trans-activator gene of HTLV-III is essential for virus replication. Nature 320:367–371PubMedCrossRef
60.
go back to reference Ghosh D (1992) Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat. J Virol 66:586–590PubMed Ghosh D (1992) Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat. J Virol 66:586–590PubMed
61.
go back to reference Soudeyns H, Geleziunas R, Shyamala G, Hiscott J, Wainberg MA (1993) Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology 194:758–768PubMedCrossRef Soudeyns H, Geleziunas R, Shyamala G, Hiscott J, Wainberg MA (1993) Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology 194:758–768PubMedCrossRef
62.
go back to reference Kino T, Kopp JB, Chrousos GP (2000) Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: direct protective effects at variance with clinical phenomenology. J Steroid Biochem Mol Biol 75:283–290PubMedCrossRef Kino T, Kopp JB, Chrousos GP (2000) Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: direct protective effects at variance with clinical phenomenology. J Steroid Biochem Mol Biol 75:283–290PubMedCrossRef
63.
go back to reference Markham PD, Salahuddin SZ, Popovic M, Patel A, Veren K, Fladager A, Orndorff S, Gallo RC (1985) Advances in the isolation of HTLV-III from patients with AIDS and AIDS-related complex and from donors at risk. Cancer Res 45:4588s–4591sPubMed Markham PD, Salahuddin SZ, Popovic M, Patel A, Veren K, Fladager A, Orndorff S, Gallo RC (1985) Advances in the isolation of HTLV-III from patients with AIDS and AIDS-related complex and from donors at risk. Cancer Res 45:4588s–4591sPubMed
64.
go back to reference Markham PD, Salahuddin SZ, Veren K, Orndorff S, Gallo RC (1986) Hydrocortisone and some other hormones enhance the expression of HTLV-III. Int J Cancer 37:67–72PubMedCrossRef Markham PD, Salahuddin SZ, Veren K, Orndorff S, Gallo RC (1986) Hydrocortisone and some other hormones enhance the expression of HTLV-III. Int J Cancer 37:67–72PubMedCrossRef
65.
66.
go back to reference Verdin E, Paras P, Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249–3259PubMed Verdin E, Paras P, Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249–3259PubMed
67.
go back to reference Van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112–1120PubMed Van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112–1120PubMed
68.
go back to reference Agostini I, Navarro JM, Rey F, Bouhamdan M, Spire B, Vigne R, Sire J (1996) The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol 261:599–606PubMedCrossRef Agostini I, Navarro JM, Rey F, Bouhamdan M, Spire B, Vigne R, Sire J (1996) The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol 261:599–606PubMedCrossRef
69.
go back to reference Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA (1999) Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 73:4101–4109PubMed Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA (1999) Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 73:4101–4109PubMed
70.
go back to reference Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ (1995) Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 270:25564–25569PubMedCrossRef Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ (1995) Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 270:25564–25569PubMedCrossRef
71.
go back to reference Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69:6304–6313PubMed Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69:6304–6313PubMed
72.
go back to reference Ayyavoo V, Mahalingam S, Rafaeli Y, Kudchodkar S, Chang D, Nagashunmugam T, Williams WV, Weiner DB (1997) HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 62:93–99PubMed Ayyavoo V, Mahalingam S, Rafaeli Y, Kudchodkar S, Chang D, Nagashunmugam T, Williams WV, Weiner DB (1997) HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 62:93–99PubMed
73.
go back to reference Tcherepanova I, Starr A, Lackford B, Adams MD, Routy J, Boulassel MR, Calderhead D, Healey D, Nicolette C (2009) The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PloS One 4:e5853PubMedCrossRef Tcherepanova I, Starr A, Lackford B, Adams MD, Routy J, Boulassel MR, Calderhead D, Healey D, Nicolette C (2009) The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PloS One 4:e5853PubMedCrossRef
74.
go back to reference Janket ML, Manickam P, Majumder B, Thotala D, Wagner M, Schafer EA, Collman RG, Srinivasan A, Ayyavoo V (2004) Differential regulation of host cellular genes by HIV-1 viral protein R (Vpr): cDNA microarray analysis using isogenic virus. Biochem Biophys Res Commun 314:1126–1132PubMedCrossRef Janket ML, Manickam P, Majumder B, Thotala D, Wagner M, Schafer EA, Collman RG, Srinivasan A, Ayyavoo V (2004) Differential regulation of host cellular genes by HIV-1 viral protein R (Vpr): cDNA microarray analysis using isogenic virus. Biochem Biophys Res Commun 314:1126–1132PubMedCrossRef
75.
go back to reference Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, Noronha CM, Greene WC, Wray V, Schubert U (2000) Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G 2 cell cycle arrest. J Biol Chem 275:32016–32026PubMedCrossRef Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, Kopp J, Noronha CM, Greene WC, Wray V, Schubert U (2000) Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G 2 cell cycle arrest. J Biol Chem 275:32016–32026PubMedCrossRef
76.
go back to reference Levy DN, Refaeli Y, MacGregor RR, Weiner DB (1994) Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91:10873–10877PubMedCrossRef Levy DN, Refaeli Y, MacGregor RR, Weiner DB (1994) Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91:10873–10877PubMedCrossRef
77.
go back to reference Ganser-Pornillos BK, Yeager M, Sundquist WI (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18:203–217PubMedCrossRef Ganser-Pornillos BK, Yeager M, Sundquist WI (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18:203–217PubMedCrossRef
78.
go back to reference Gramberg T, Sunseri N, Landau NR (2009) Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep 6:36–42PubMedCrossRef Gramberg T, Sunseri N, Landau NR (2009) Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep 6:36–42PubMedCrossRef
79.
go back to reference Malim MH (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364:675–687PubMedCrossRef Malim MH (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364:675–687PubMedCrossRef
80.
go back to reference Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V (2009) HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5:e1000574PubMedCrossRef Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V (2009) HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5:e1000574PubMedCrossRef
81.
go back to reference Kino T, Nordeen SK, Chrousos GP (1999) Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol 70:15–25PubMedCrossRef Kino T, Nordeen SK, Chrousos GP (1999) Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol 70:15–25PubMedCrossRef
82.
go back to reference Thotala D, Schafer EA, Majumder B, Janket ML, Wagner M, Srinivasan A, Watkins S, Ayyavoo V (2004) Structure–functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 328:89–100PubMedCrossRef Thotala D, Schafer EA, Majumder B, Janket ML, Wagner M, Srinivasan A, Watkins S, Ayyavoo V (2004) Structure–functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. Virology 328:89–100PubMedCrossRef
83.
go back to reference Kino T, Pavlakis GN (2004) Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol 23:193–205PubMedCrossRef Kino T, Pavlakis GN (2004) Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol 23:193–205PubMedCrossRef
84.
go back to reference Kino T, Martino MU, Charmandari E, Ichijo T, Chrousos GP (2005) HIV-1 accessory protein Vpr inhibits the effect of insulin on the foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54:23–31PubMedCrossRef Kino T, Martino MU, Charmandari E, Ichijo T, Chrousos GP (2005) HIV-1 accessory protein Vpr inhibits the effect of insulin on the foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 54:23–31PubMedCrossRef
85.
go back to reference Kamata M, Watanabe N, Nagaoka Y, Chen IS (2008) Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. J Virol 82:5672–5682PubMedCrossRef Kamata M, Watanabe N, Nagaoka Y, Chen IS (2008) Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2. J Virol 82:5672–5682PubMedCrossRef
86.
go back to reference Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB (1997) HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 3:1117–1123PubMedCrossRef Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB (1997) HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med 3:1117–1123PubMedCrossRef
87.
go back to reference Schafer EA, Venkatachari NJ, Ayyavoo V (2006) Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antiviral Res 72:224–232PubMedCrossRef Schafer EA, Venkatachari NJ, Ayyavoo V (2006) Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antiviral Res 72:224–232PubMedCrossRef
88.
go back to reference Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist A, Thorell S, Ohman L, Greer J, Gustafsson J, Carlstedt-Duke J, Carlquist M (2003) The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278:22748–22754PubMedCrossRef Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, Alarcon M, Calles K, Engström O, Harlan J, Muchmore S, Ramqvist A, Thorell S, Ohman L, Greer J, Gustafsson J, Carlstedt-Duke J, Carlquist M (2003) The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 278:22748–22754PubMedCrossRef
89.
go back to reference Fakruddin JM, Laurence J (2005) HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 150:67–78PubMedCrossRef Fakruddin JM, Laurence J (2005) HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 150:67–78PubMedCrossRef
90.
go back to reference Muthumani K, Choo AY, Premkumar A, Hwang DS, Thieu KP, Desai BM, Weiner DB (2005) Human immunodeficiency virus type 1 (HIV-1) Vpr- regulated cell death: insights into mechanism. Cell Death Differ 12:962–970PubMedCrossRef Muthumani K, Choo AY, Premkumar A, Hwang DS, Thieu KP, Desai BM, Weiner DB (2005) Human immunodeficiency virus type 1 (HIV-1) Vpr- regulated cell death: insights into mechanism. Cell Death Differ 12:962–970PubMedCrossRef
91.
go back to reference Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72PubMedCrossRef Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60–72PubMedCrossRef
92.
go back to reference Patel CA, Mukhtar M, Pomerantz RJ (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74:9717–9726PubMedCrossRef Patel CA, Mukhtar M, Pomerantz RJ (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74:9717–9726PubMedCrossRef
93.
go back to reference Majumder B, Venkatachari NJ, Schafer EA, Janket ML, Ayyavoo V (2007) Dendritic Cells Infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha. J Virol 81:7388–7399PubMedCrossRef Majumder B, Venkatachari NJ, Schafer EA, Janket ML, Ayyavoo V (2007) Dendritic Cells Infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha. J Virol 81:7388–7399PubMedCrossRef
94.
go back to reference Kim KD, Choe YK, Choe IS, Lim JS (2001) Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol 69:426–434PubMed Kim KD, Choe YK, Choe IS, Lim JS (2001) Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol 69:426–434PubMed
95.
go back to reference Kotitschke A, Sadie-Van Gijsen H, Avenant C, Fernandes S, Hapgood JP (2009) Genomic and nongenomic cross talk between the gonadotropin-releasing hormone receptor and glucocorticoid receptor signaling pathways. Mol Endocrinol 23:1726–1745PubMedCrossRef Kotitschke A, Sadie-Van Gijsen H, Avenant C, Fernandes S, Hapgood JP (2009) Genomic and nongenomic cross talk between the gonadotropin-releasing hormone receptor and glucocorticoid receptor signaling pathways. Mol Endocrinol 23:1726–1745PubMedCrossRef
96.
go back to reference Avenant C, Kotitschke A, Hapgood JP (2010) Glucocorticoid receptor phosphorylation modulates transcription efficacy through GRIP-1 recruitment. Biochemistry 49:972–985PubMedCrossRef Avenant C, Kotitschke A, Hapgood JP (2010) Glucocorticoid receptor phosphorylation modulates transcription efficacy through GRIP-1 recruitment. Biochemistry 49:972–985PubMedCrossRef
97.
go back to reference Agostini I, Popov S, Hao T, Li JH, Dubrovsky L, Chaika O, Chaika N, Lewis R, Bukrinsky M (2002) Phosphorylation of Vpr Regulates HIV Type 1 Nuclear Import and Macrophage Infection. AIDS Res Hum Retroviruses 18:283–288PubMedCrossRef Agostini I, Popov S, Hao T, Li JH, Dubrovsky L, Chaika O, Chaika N, Lewis R, Bukrinsky M (2002) Phosphorylation of Vpr Regulates HIV Type 1 Nuclear Import and Macrophage Infection. AIDS Res Hum Retroviruses 18:283–288PubMedCrossRef
98.
go back to reference Ishaq M, DeGray G, Mou K, Aguilera A, Yang J, Lempicki RA, Hazen A, Natarajan V (2007) Zap70 signaling pathway mediates glucocorticoid receptor-dependent transcriptional activation: role in the regulation of annexin 1 expression in T cells. J Immunol 179:3851–3858PubMed Ishaq M, DeGray G, Mou K, Aguilera A, Yang J, Lempicki RA, Hazen A, Natarajan V (2007) Zap70 signaling pathway mediates glucocorticoid receptor-dependent transcriptional activation: role in the regulation of annexin 1 expression in T cells. J Immunol 179:3851–3858PubMed
99.
go back to reference Collingwood TN, Urnov FD, Wolffe AP (1999) Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23:255–275PubMedCrossRef Collingwood TN, Urnov FD, Wolffe AP (1999) Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23:255–275PubMedCrossRef
100.
go back to reference Ratajczak T, Ward BK, Minchin RF (2003) Immunophilin Chaperones in Steroid Receptor Signalling. Curr Top Med Chem 3:1348–1357PubMedCrossRef Ratajczak T, Ward BK, Minchin RF (2003) Immunophilin Chaperones in Steroid Receptor Signalling. Curr Top Med Chem 3:1348–1357PubMedCrossRef
101.
go back to reference Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G, Chana G, Soontornniyomkij V, Achim CL (2009) Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 4:218–226PubMedCrossRef Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G, Chana G, Soontornniyomkij V, Achim CL (2009) Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 4:218–226PubMedCrossRef
102.
go back to reference Wang J, Shackelford JM, Selliah N, Shivers DK, O’Neill E, Garcia JV, Muthumani K, Weiner D, Yu X, Gabuzda D, Finkel TH (2008) The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol 27:267–277PubMedCrossRef Wang J, Shackelford JM, Selliah N, Shivers DK, O’Neill E, Garcia JV, Muthumani K, Weiner D, Yu X, Gabuzda D, Finkel TH (2008) The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol 27:267–277PubMedCrossRef
103.
go back to reference Hapgood JP, Koubovec D, Louw A, Africander D (2004) Not all progestins are the same: implications for usage. Trends Pharmacol Sci 25:554–557PubMedCrossRef Hapgood JP, Koubovec D, Louw A, Africander D (2004) Not all progestins are the same: implications for usage. Trends Pharmacol Sci 25:554–557PubMedCrossRef
104.
go back to reference Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP (2005) Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242:23–32PubMedCrossRef Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP (2005) Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242:23–32PubMedCrossRef
105.
go back to reference Ronacher K, Hadley K, Avenant C, Stubsrud E, Louw A, Hapgood JP (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 299:219–231PubMedCrossRef Ronacher K, Hadley K, Avenant C, Stubsrud E, Louw A, Hapgood JP (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 299:219–231PubMedCrossRef
106.
go back to reference Hewitt RG, Parsa N, Gugino L (2001) Women’s health. The role of gender in HIV progression. AIDS Read 11:29–33PubMed Hewitt RG, Parsa N, Gugino L (2001) Women’s health. The role of gender in HIV progression. AIDS Read 11:29–33PubMed
107.
go back to reference Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J (1999) Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 5:535–541PubMedCrossRef Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J (1999) Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 5:535–541PubMedCrossRef
108.
go back to reference Greenblatt RM, Ameli N, Grant RM, Bacchetti P, Taylor RN (2000) Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 181:82–90PubMedCrossRef Greenblatt RM, Ameli N, Grant RM, Bacchetti P, Taylor RN (2000) Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 181:82–90PubMedCrossRef
109.
go back to reference Kojic EM, Cu-Uvin S (2007) Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 19:464–469PubMedCrossRef Kojic EM, Cu-Uvin S (2007) Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 19:464–469PubMedCrossRef
110.
go back to reference Asin SN, Heimberg AM, Eszterhas SK, Rollenhagen C, Howell AL (2008) Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses 24:701–716PubMedCrossRef Asin SN, Heimberg AM, Eszterhas SK, Rollenhagen C, Howell AL (2008) Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses 24:701–716PubMedCrossRef
111.
go back to reference Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194:S51–S58PubMedCrossRef Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194:S51–S58PubMedCrossRef
112.
go back to reference Andrieu JM, Lu W, Levy R (1995) Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 171:523–530PubMed Andrieu JM, Lu W, Levy R (1995) Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 171:523–530PubMed
113.
go back to reference McComsey GA, Whalen CC, Mawhorter SD, Asaad R, Valdez H, Patki AH, Klaumunzner J, Gopalakrishna KV, Calabrese LH, Lederman MM (2001) Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 15:321–327PubMedCrossRef McComsey GA, Whalen CC, Mawhorter SD, Asaad R, Valdez H, Patki AH, Klaumunzner J, Gopalakrishna KV, Calabrese LH, Lederman MM (2001) Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 15:321–327PubMedCrossRef
114.
go back to reference Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, Hoffmann MK, Horowitz HW (2001) Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons. J Infect Dis 184:1328–1330PubMedCrossRef Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, Hoffmann MK, Horowitz HW (2001) Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons. J Infect Dis 184:1328–1330PubMedCrossRef
115.
go back to reference Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM (2003) A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr 32:281–286PubMedCrossRef Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM (2003) A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr 32:281–286PubMedCrossRef
116.
go back to reference Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC (2003) A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis 188:531–536PubMedCrossRef Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC (2003) A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis 188:531–536PubMedCrossRef
117.
go back to reference Andrieu J, Lu W (2004) Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2:17PubMedCrossRef Andrieu J, Lu W (2004) Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2:17PubMedCrossRef
118.
go back to reference Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, Ducar C, Ellner JJ, Whitworth JA, Mugerwa R, Johnson JL, Okwera A (2004) A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 190:869–878PubMedCrossRef Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, Ducar C, Ellner JJ, Whitworth JA, Mugerwa R, Johnson JL, Okwera A (2004) A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 190:869–878PubMedCrossRef
119.
go back to reference Panayotakopoulos GD, Day S, Peters BS, Kulasegaram R (2006) Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines. Int J STD AIDS 17:567–568PubMedCrossRef Panayotakopoulos GD, Day S, Peters BS, Kulasegaram R (2006) Severe osteoporosis and multiple fractures in an AIDS patient treated with short-term steroids for lymphoma: a need for guidelines. Int J STD AIDS 17:567–568PubMedCrossRef
120.
go back to reference Rosen J, Miner JN (2005) The search for safer glucocorticoid receptor ligands. Endocr Rev 26:452–464PubMedCrossRef Rosen J, Miner JN (2005) The search for safer glucocorticoid receptor ligands. Endocr Rev 26:452–464PubMedCrossRef
122.
go back to reference Geeraert L, Kraus G, Pomerantz RJ (2008) Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 59:487–501PubMedCrossRef Geeraert L, Kraus G, Pomerantz RJ (2008) Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 59:487–501PubMedCrossRef
123.
go back to reference Amini S, Saunders M, Kelley K, Khalili K, Sawaya BE (2004) Interplay between HIV-1 Vpr and Sp1 Modulates p21 (WAF1) gene expression in human astrocytes. J Biol Chem 279:46046–46056PubMedCrossRef Amini S, Saunders M, Kelley K, Khalili K, Sawaya BE (2004) Interplay between HIV-1 Vpr and Sp1 Modulates p21 (WAF1) gene expression in human astrocytes. J Biol Chem 279:46046–46056PubMedCrossRef
124.
go back to reference Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ (1998) HIV transcriptional activation by the accessory protein, Vpr, is mediated by the p300 co-activator. Proc Natl Acad Sci USA 95:5281–5286PubMedCrossRef Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ (1998) HIV transcriptional activation by the accessory protein, Vpr, is mediated by the p300 co-activator. Proc Natl Acad Sci USA 95:5281–5286PubMedCrossRef
125.
go back to reference Marcello A, Zoppé M, Giacca M (2001) Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 51:175–181PubMedCrossRef Marcello A, Zoppé M, Giacca M (2001) Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 51:175–181PubMedCrossRef
126.
go back to reference Kino T, Tsukamoto M, Chrousos GP (2002) Transcription factor TFIIH components enhance the GR coactivator activity but not the cell cycle-arresting activity of the human immunodeficiency virus type-1 protein Vpr. Biochem Biophys Res Commun 298:17–23PubMedCrossRef Kino T, Tsukamoto M, Chrousos GP (2002) Transcription factor TFIIH components enhance the GR coactivator activity but not the cell cycle-arresting activity of the human immunodeficiency virus type-1 protein Vpr. Biochem Biophys Res Commun 298:17–23PubMedCrossRef
Metadata
Title
Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis
Authors
Janet Patricia Hapgood
Michele Tomasicchio
Publication date
01-07-2010
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 7/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-010-0678-0

Other articles of this Issue 7/2010

Archives of Virology 7/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.